Biotech Values

[hptaxis]

Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK(R), VX-222 and Ribavirin in People with Genotype 1 Hepatitis C
- Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 weeks -
http://www.marketwatch.com/story/vertex-announces-12-week-on-treatment-data-and-svr4-from-phase-2-study-of-interferon-free-all-oral-treatment-regimen-of-incivekr-vx-222-and-ribavirin-in-people-with-genotype-1-hepatitis-c-2012-02-23